Glipiz Tablet
Glipizide
5mg
Nepal Pharmaceuticals Pvt. Ltd.
| Pack size | 1 |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 1.50 NPR |
Indications
Glipiz Tablet is used for:
Type 2 DM
Adult Dose
Oral
Type 2 diabetes mellitus
Adult: Initially, 2.5-5 mg daily as a single dose. Adjust at intervals of several days in increments of 2.5-5 mg daily.
Doses >15 mg may be given in 2 divided doses. Max: 40 mg daily.
Extended-release tablets
Initial: 5 mg/day PO given with breakfast; dose adjustment based on blood glucose should not be done more frequently than every 7 days
Maintenance range: 5-10 mg PO qDay; not to exceed 20 mg/day
Elderly:
2.5 mg PO qDay initially; increase by 2.5-5 mg/day every 1-2 weeks as determined by blood glucose response at intervals of several days
May switch to extended release once daily tablets at the nearest equivalent total daily dose or lower end of recommended range; not to exceed 20 mg/day
Hepatic impairment: 2.5 mg PO qDay initially (immediate release); extended release not studied
Severe: Contraindicated.
Child Dose
Safety and efficacy not established
Renal Dose
Renal impairment: Not studied; if GFR <50 mL/min, may decrease dose by 50%
Severe: Contraindicated.
Administration
Immediate-release: Should be taken on an empty stomach. Take ½ hr before meals.
Extended-release: Should be taken with food. Swallow whole, do not chew/crush/divide.
Contra Indications
Hypersensitivity. Type 1 DM; ketoacidosis; severe renal or hepatic insufficiency. Pregnancy, lactation.
Precautions
Hypoglycaemia, stress, elderly. Thyroid impairment; moderate hepatic or renal impairment. Monitor blood glucose concentration.
Lactation: Not known if crosses into breast milk; not recommended
Pregnancy-Lactation
Interactions
Increased plasma concentration w/ certain antifungals (e.g. miconazole, fluconazole). Protein-bound drugs (e.g. NSAIDs, other sulfonamides, oral anticoagulants, hydantoins), probenecid, MAOIs, and chloramphenicol may potentiate hypoglycaemic action of glipizide. Diminished therapeutic effect w/ thiazides, other diuretics, phenothiazines, thyroid agents, oestrogens, OC, phenytoin, nicotinic acid, sympathomimetics, Ca channel blockers, rifampicin and isoniazid. Concomitant use w/ beta-blockers may impair glucose tolerance, increase frequency or severity of hypoglycaemia and block hypoglycaemia-induced tachycardia. Decreased serum concentration w/ colesevelam.
Adverse Effects
Side effects of Glipizide :
GI upsets, diarrhoea, nausea; allergic skin reactions, leucopenia, thrombocytopenia, agranulocytosis, hyponatraemia; jaundice; haemolytic anaemia, pancytopenia.
Potentially Fatal: Hypoglycaemia in presence of renal or hepatic damage and alcohol.
Mechanism of Action
Glipizide stimulates insulin release from pancreatic ?-cells and reduces glucose output from the liver. It also increases insulin sensitivity at peripheral target sites.
Note
Glipiz 5mg Tablet manufactured by Nepal Pharmaceuticals Pvt. Ltd.. Its generic name is Glipizide. Glipiz is availble in Nepal.
Farmaco Nepal drug index information on Glipiz Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.